4 completed, 1 active not recruiting, 1 not yet recruiting, 1 recruiting. 8 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Completed 4, Active not recruiting 1, Not yet recruiting 1, Recruiting 1, Unknown 1 |
Follow Prostate Cancer Recurrent: new trials by email Literature Review of Prostate Cancer Recurrent trials Research Report on Prostate Cancer Recurrent
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer 64Cu-SAR-bisPSMA - Prostate Cancer, Prostate Cancer Patients With Detectable PSA Following Prostatectomy | Phase 3 | Active not recruiting | Clarity Pharmaceuticals Ltd | 220 | 2025-05-16 | 2026-05-14 |
| A Multicenter, Open-label, Prospective Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Participants With Suspected Recurrent Prostate Cancer After Radical Treatment INR101 - Prostate Cancer Recurrent | Phase 3 | Not yet recruiting | Yunhe Pharmaceutical (Tianjin) Co., Ltd | 110 | 2025-04-01 | 2025-04-11 |
| Metastasis-directed Therapy for Oligorecurrent Prostate Cancer Radiotherapy (SBRT) and/or surgery (metastasectomy), Androgen deprivation therapy, Androgen receptor targeted therapy - Prostate Cancer, Prostate Cancer Recurrent | Phase 3 | Recruiting | Universitaire Ziekenhuizen KU Leuven | 873 | 2022-04-20 | 2024-07-03 |
| Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer [18F]PSMA-1007 - Prostate Cancer, Prostate Cancer Recurrent | Phase 3 | Completed | ABX advanced biochemical compounds GmbH | 136 | 2021-08-27 | 2025-07-15 |
| Safety and Efficacy of [18F]PSMA-1007 Injection in Suspected Persistent or Recurrent Prostate Cancer. [18F] PSMA-1007 Injection - Prostate Cancer Recurrent, Recurrent Prostate Cancer | Phase 3 | Completed | Centre for Probe Development and Commercialization | 100 | 2020-12-21 | 2024-02-07 |
| A Prospective Study on 18F-DCFPyL PET/CT Imaging in Biochemical Recurrence of Prostate Cancer DCFPyL - Prostate Cancer Recurrent | Phase 3 | Unknown | Curium PET France | 217 | 2020-07-07 | 2021-02-02 |
| F-18-PSMA-1007 Versus F-18-Fluorocholine PET in Patients With Biochemical Recurrence F-18-PSMA-1007, F-18-Fluorocholine - Prostate Cancer, Prostate Cancer Recurrent | Phase 3 | Completed | ABX advanced biochemical compounds GmbH | 200 | 2019-03-06 | 2021-06-29 |
| Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer 18F-DCFPyL, PET/CT Imaging - Prostate Cancer, Prostate Adenocarcinoma | Phase 3 | Completed | Progenics Pharmaceuticals, Inc. | 208 | 2018-11-27 | 2021-06-14 |
Prostatic Neoplasms (6) · Disease (1) · Neoplasm Metastasis (1)
Genital Diseases (6) · Genital Diseases, Male (6) · Genital Neoplasms, Male (6) · Male Urogenital Diseases (6) · Neoplasms (6) · Neoplasms by Site (6) · Prostatic Diseases (6) · Urogenital Diseases (6) · Urogenital Neoplasms (6) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Neoplastic Processes (1)
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid (1) · Androgen Antagonists (1) · Metastasectomy (1) · Radiosurgery (1) · Radiotherapy (1)
ABX advanced biochemical compounds GmbH (2) · Centre for Probe Development and Commercialization (1) · Clarity Pharmaceuticals Ltd (1) · Curium PET France (1) · Progenics Pharmaceuticals, Inc. (1) · Universitaire Ziekenhuizen KU Leuven (1) · Yunhe Pharmaceutical (Tianjin) Co., Ltd (1)
United States (3) · Canada (2) · France (2) · Australia (1) · Belgium (1) · China (1) · Netherlands (1) · Switzerland (1)
Hongcheng Shi (1) · Jessica D Jensen (1) · Jianming Guo (1)